ArticleClinical pharmacokinetics2026
Understanding Pharmacokinetic Variability of Pomalidomide: A Physiologically Based Pharmacokinetic Analysis of Disease-Related Physiology, Ethnicity, Hepatic Impairment, Food Effects, Drug Interactions, and Smoking.
Article in Clinical pharmacokinetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveUnderstanding interindividual pharmacokinetic variability and potential for drug interactions is of clinical importance for pomalidomide given its long-term use in patients with relapsed and/or refractory multiple myeloma (RRMM). This study aimed to develop a physiologically based pharmacokinetic (PBPK) model of pomalidomide that integrates multiple sources of pharmacokinetic (PK) variability, including RRMM-related physiology, ethnicity, hepatic impairment, food effects, drug interactions, and cigarette smoking.
methodsA PBPK model was developed incorporating in silico-predicted and experimentally measured physicochemical and biopharmaceutical properties, together with physiological parameters representing disease state, liver function, prandial status, and ethnic differences. Changes in PK and systemic exposure associated with multiple sources of variability, evaluated as shifts in central tendency, were predicted by the model.
resultsThe model provided reliable estimates of observed PK profiles across all evaluated scenarios, with more than 90% of predicted PK metrics falling within 0.80- to 1.25-fold of clinically reported values. Changes in pharmacokinetics associated with RRMM in people of European and Japanese ancestry, as well as severity-graded hepatic impairment, were reasonably predicted, despite slight overestimation of systemic exposure in severe hepatic impairment (prediction-to-reported ratio ≈ 1.55). Physiologically based pharmacokinetic model predictions of the effect of co-administration with high-fat, high-calorie meals (15-30% reduction in C
conclusionsOverall, this work highlights the utility of a PBPK modelling framework in providing mechanistic insights into multiple sources of pomalidomide PK variability, with potential broader applicability to other drugs.
Identifiers
42814376What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.